Aug. 13 at 2:57 PM
$BFRI Overall, great earnings call. Record Q2 GAAP EPS and Record Q2 Revenue. Right now the only obstacles that remain are our known FDA timelines for other Ameluz applications to include sBCC, Actinic Keratosis on additional areas of the body, and Acne as well as the International Trade Commission exclusion order.
For more clarity on the International Trade Commission exclusion order, I did the math. The exclusion order currently affects 243 lamps out of 801. A regular BF-RhodoLED costs approximately
$5,495.00 therefore let's assume double for the XL just for the sake of keeping the math easy as I don't know how much the XL actually costs. Even in the worst case scenario event that Sun Pharma forces
$BFRI to fully replace all 243 lamps for
$2.67MIL and we continue to use
$1.658MIL per quarter, we only spend
$4.331MIL. We have
$4.659MIL to work with, we are fine.
God Bless and Godspeed guys, things are looking so so good over here.
